Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2021 Filed Mar 3, 2021 00:55 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,846 | $121.58 | $589,176.68 |
DisclosureSEC source: 0001415889-21-001213 · form4-03022021_040334.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,344 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:01 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 9,433 | $121.58 | $1,146,864.14 |
DisclosureSEC source: 0001415889-21-001215 · form4-03022021_050325.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,707 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:59 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 5,000 | $121.58 | $607,900.00 |
DisclosureSEC source: 0001415889-21-001214 · form4-03022021_040329.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,337 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:05 UTC |
Wellisch Alejandro DSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 5,612 | $121.58 | $682,306.96 |
DisclosureSEC source: 0001415889-21-001216 · form4-03022021_050346.xml · nonDerivative · entry 2 Wellisch Alejandro D · CIK 0001717526 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,063 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:05 UTC |
Wellisch Alejandro DSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 16,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001216 · form4-03022021_050346.xml · nonDerivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,675 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:08 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
Tax withholdingCommon shares without par value | 43,292 | $121.58 | $5,263,441.36 |
DisclosureSEC source: 0001415889-21-001217 · form4-03022021_050320.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,105,195 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:11 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 4,135 | $121.58 | $502,733.30 |
DisclosureSEC source: 0001415889-21-001218 · form4-03022021_050317.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,495 Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 23:05 UTC |
Kumbier MichelleDirector
|
PurchaseCommon shares without par value | 2,040 | $122.50 | $249,900.00 |
DisclosureSEC source: 0001415889-21-000968 · form4-02252021_030242.xml · nonDerivative · entry 1 Kumbier Michelle · CIK 0001640036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,296 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.498 to $122.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 23:24 UTC |
Boudreau Philip PVICE PRESIDENT
|
Tax withholdingCommon shares without par value | 937 | $123.04 | $115,288.48 |
DisclosureSEC source: 0001415889-21-000885 · form4-02232021_030207.xml · nonDerivative · entry 2 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,580 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:05 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 400 | $121.84 | $48,734.00 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · nonDerivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,706 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:05 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 780 | $123.04 | $95,971.20 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,106 Read SEC document |
| February 22, 2021 Filed Feb 24, 2022 01:23 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 400 | $119.31 | $47,722.68 |
DisclosureSEC source: 0001415889-22-001742 · form4-02232022_050234.xml · nonDerivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,965 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:58 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 47,993 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000882 · form4-02232021_020209.xml · derivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Underlying: Common Shares · 47,993 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,997 on February 19, 2022, 15,998 on February 19, 2023, and 15,998 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:58 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 9,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000882 · form4-02232021_020209.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,379 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:17 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 87,422 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000883 · form4-02232021_030230.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,422 Underlying: Common Shares · 87,422 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,140 on February 19, 2022, 29,141 on February 19, 2023, and 29,141 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:17 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 17,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000883 · form4-02232021_030230.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,951 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:20 UTC |
BIRD ROGERSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 66,658 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000884 · form4-02232021_030214.xml · derivative · entry 2 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,658 Underlying: Common Shares · 66,658 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,219 on February 19, 2022, 22,219 on February 19, 2023, and 22,220 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:20 UTC |
BIRD ROGERSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 13,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000884 · form4-02232021_030214.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:29 UTC |
BRYNELSEN CHARLESSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 39,994 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000886 · form4-02232021_030225.xml · derivative · entry 2 BRYNELSEN CHARLES · CIK 0001712459 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,994 Underlying: Common Shares · 39,994 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,331 on February 19, 2022, 13,331 on February 19, 2023, and 13,332 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:29 UTC |
BRYNELSEN CHARLESSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 7,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000886 · form4-02232021_030225.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,612 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:24 UTC |
Boudreau Philip PVICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 25,613 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000885 · form4-02232021_030207.xml · derivative · entry 4 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,613 Underlying: Common Shares · 25,613 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,537 on February 19, 2022, 8,538 on February 19, 2023, and 8,538 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:24 UTC |
Boudreau Philip PVICE PRESIDENT
|
GrantCommon shares without par value | 4,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000885 · form4-02232021_030207.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,517 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:34 UTC |
CAPEK JOHN MEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 71,070 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000887 · form4-02232021_030259.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,070 Underlying: Common Shares · 71,070 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,690 on February 19, 2022, 23,690 on February 19, 2023, and 23,690 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:34 UTC |
CAPEK JOHN MEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 13,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000887 · form4-02232021_030259.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,665 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:41 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 53,326 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000888 · form4-02232021_030249.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,326 Underlying: Common Shares · 53,326 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,775 on February 19, 2022, 17,775 on February 19, 2023, and 17,776 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:41 UTC |
DALE MICHAEL DSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 10,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000888 · form4-02232021_030249.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,166 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:45 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 71,070 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000890 · form4-02232021_030231.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,070 Underlying: Common Shares · 71,070 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,690 on February 19, 2022, 23,690 on February 19, 2023, and 23,690 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:45 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 13,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000890 · form4-02232021_030231.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,939 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:47 UTC |
Ford Robert BDirector · PRESIDENT AND CEO
|
GrantOption (right to buy) · Derivative | 359,090 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000891 · form4-02232021_030205.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,090 Underlying: Common Shares · 359,090 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 119,696 on February 19, 2022, 119,697 on February 19, 2023, and 119,697 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:47 UTC |
Ford Robert BDirector · PRESIDENT AND CEO
|
GrantCommon shares without par value | 70,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000891 · form4-02232021_030205.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,683 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:51 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 123,966 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000892 · form4-02232021_030200.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,966 Underlying: Common Shares · 123,966 shares Expires 2031-02-18 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 41,322 on February 19, 2022, 41,322 on February 19, 2023, and 41,322 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:51 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 24,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000892 · form4-02232021_030200.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,486 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:53 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 78,966 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000893 · form4-02232021_030243.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,966 Underlying: Common Shares · 78,966 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,322 on February 19, 2022, 26,322 on February 19, 2023, and 26,322 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:53 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 15,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000893 · form4-02232021_030243.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,409 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:56 UTC |
Karam SammySENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 53,326 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000894 · form4-02232021_030246.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,326 Underlying: Common Shares · 53,326 shares Expires 2031-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,775 on February 19, 2022, 17,775 on February 19, 2023, and 17,776 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:57 UTC |
LANE ANDREW HEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 71,070 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000895 · form4-02232021_030230.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,070 Underlying: Common Shares · 71,070 shares Expires 2031-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,690 on February 19, 2022, 23,690 on February 19, 2023, and 23,690 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:01 UTC |
MANNING JOSEPH JSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 66,658 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000896 · form4-02232021_040228.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,658 Underlying: Common Shares · 66,658 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,219 on February 19, 2022, 22,219 on February 19, 2023, and 22,220 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:01 UTC |
MANNING JOSEPH JSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 13,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000896 · form4-02232021_040228.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,707 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 10,978 shares and employee stock options to purchase shares 178,060 in the aggregate to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:05 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 69,266 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · derivative · entry 5 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,266 Underlying: Common Shares · 69,266 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,088 on February 19, 2022, 23,089 on February 19, 2023, and 23,089 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:05 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 13,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000897 · form4-02232021_040247.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,886 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:07 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 47,993 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000898 · form4-02232021_040257.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Underlying: Common Shares · 47,993 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,997 on February 19, 2022, 15,998 on February 19, 2023, and 15,998 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:07 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 9,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000898 · form4-02232021_040257.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,817 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:10 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 98,708 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000899 · form4-02232021_040224.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,708 Underlying: Common Shares · 98,708 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,902 on February 19, 2022, 32,903 on February 19, 2023, and 32,903 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:10 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 19,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000899 · form4-02232021_040224.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,690 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:12 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 63,991 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000900 · form4-02232021_040210.xml · derivative · entry 2 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,991 Underlying: Common Shares · 63,991 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,330 on February 19, 2022, 21,330 on February 19, 2023, and 21,331 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:12 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 12,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000900 · form4-02232021_040210.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,190 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:15 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 98,708 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000901 · form4-02232021_040251.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,708 Underlying: Common Shares · 98,708 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,902 on February 19, 2022, 32,903 on February 19, 2023, and 32,903 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:15 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 19,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000901 · form4-02232021_040251.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,337 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:16 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 58,659 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000902 · form4-02232021_040207.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,659 Underlying: Common Shares · 58,659 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,553 on February 19, 2022, 19,553 on February 19, 2023, and 19,553 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:16 UTC |
Watkin JaredSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 11,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000902 · form4-02232021_040207.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,140 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.